Neurol. praxi. 2015;16(4):223-226

Drug induced hepatopathy after fingolimod treatment

MUDr. Petra Praksová, Ph.D., MUDr. Magdaléna Hladíková, Ph.D.
Neurologická klinika LF MU a FN Brno

We report a case of 34-year-old man with multiple sclerosis with recurrent hepatopathy of toxicity grade 3 after Gilenya treatment in the first 6 months of our treatment. We must twice discontinue treatment with Gilenya due to hepatopathy. There was no episode of recurrent hepatopathy in the next 1,5 year. Our patient is clinically and radiologically stabilized.

Keywords: multiple sclerosis, drug induced hepatopathy, fingolimod

Published: September 19, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Praksová P, Hladíková M. Drug induced hepatopathy after fingolimod treatment. Neurol. praxi. 2015;16(4):223-226.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. AIDS Clinical Trials Group. Table of Grading Severity of Adult Adverse Experiences. Rockville, MD: Division of AIDS, National Institute of Allergy and Infectious Diseases; Bethesda, 1996.
    2. Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD.Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014; 13(6): 545-556. Go to original source...
    3. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L. TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010; 362: 402-415. Go to original source... Go to PubMed...
    4. Cohen JA, Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol. 2011; 69(5): 759-777. Go to original source...
    5. Cullen JM. Mechanistic classification of liver injury. Toxicol Pathol. 2005; 33(1): 6-8. Go to original source...
    6. Fazekas F, Berger T, Fabjan TH, Ledinek AH, Jakab G, Komoly S, Kraus J, Kurča E, Kyriakides T, Lisý L, Milanov I, Panayiotou P, Jazbec SS, Taláb R, Traykov L, Turčáni P, Vass K, Vella N, Havrdová E. Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.Wien Med Wochenschr. 2012; 162(15-16): 354-366. Go to original source... Go to PubMed...
    7. Glasa J, Glasová H. Liekové poškodenie pečenev ambulancii praktického lekára. Via pract., 2008; 5(4/5): 178-181.
    8. Hůlek P, Hrubá I. Poškození jater léky. Doporučené postupy pro praktické lékaře. 2002. Dokument dostupný na: http://www.virova-hepatitida.cz/dokumenty/doporucene_postupy_leky.pdf.
    9. Ibanez L, Perez E, Vidal X, Laporte JR, Group d'Estudi Multicenteric d'Hepatotoxicitat Aguda de Barcelona (GEMHAB). Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J Hepatol 2002; 37: 592-600. Go to original source... Go to PubMed...
    10. Izquierdo G, O'Connor P, Montalban X, von Rosenstiel P, Cremer M, de Vera A, Sfikas N, Francis G, Radue E, Kappos L. Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis. Mult Scler. 2014; 20(7): 877-881. Go to original source... Go to PubMed...
    11. Kunitomo Adachi, Kenji Chiba. FTY720 Story. Its Discovery and the Following Accelerated Development of Sphingosine 1-Phosphate Receptor Agonists as Immunomodulators Based on Reverse Pharmacology. Perspect Medicin Chem. 2007; 1: 11-23. Go to original source... Go to PubMed...
    12. Sellebjerg F, S?rensen PS. Therapeutic interference with leukocyte recirculation in multiple sclerosis. Eur J Neurol. 2015; 22(3): 434-442. Go to original source...
    13. SÚKL. Souhrn údajů o přípravku. Dokument dostupný na: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/002202/WC500104528.pdf.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.